Novel natural inhibitors targeting B-RAF(V600E) by computational study

References

• Pavri SN, Clune J, Ariyan S, et al. Malignant Melanoma: beyond the Basics. Plast Reconstr Surg. 2016;138(2):330e–40e.
   PubMed Web of Science ®Google Scholar
• Wan M, Zhuang B, Dai X, et al. A new metabolic signature contributes to disease progression and predicts worse survival in melanoma. Bioengineered. 2020;11(1):1099–1111.
   PubMed Web of Science ®Google Scholar
• Pasquali S, Hadjinicolaou AV, Chiarion Sileni V, et al. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2(2):Cd011123.
   PubMedGoogle Scholar
• Cheng PF. Medical bioinformatics in melanoma. Curr Opin Oncol. 2018;30(2):113–117.
   PubMed Web of Science ®Google Scholar
• Kızılbey K, Mansuroğlu B, Derman S, et al. An In vivo study: adjuvant activity of poly-n-vinyl-2-pyrrolidone-co-acrylic acid on immune responses against Melanoma synthetic peptide. Bioengineered. 2018;9(1):134–143.
   PubMed Web of Science ®Google Scholar
• Abbas O, Miller DD, Bhawan J. Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol. 2014;36(5):363–379.
   PubMed Web of Science ®Google Scholar
• Cuevas LM, Daud AI. Immunotherapy for melanoma. Semin Cutan Med Surg. 2018;37(2):127–131.
   PubMed Web of Science ®Google Scholar
• Cohen JV, Buchbinder EI. The Evolution of Adjuvant Therapy for Melanoma. Curr Oncol Rep. 2019;21(12):106.
   PubMed Web of Science ®Google Scholar
• Quaglino P, Fava P, Brizio M, et al. Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak: experience from an Italian skin cancer unit. Future Oncol. 2021;17(7):759–761.
   PubMed Web of Science ®Google Scholar
• Degirmenci U, Wang M, Hu J. Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy. Cells. 2020;9(1):1.
   Web of Science ®Google Scholar
• Rabbie R, Ferguson P, Molina-Aguilar C, et al. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247(5):539–551.
   PubMed Web of Science ®Google Scholar
• Sun J, Carr MJ, Khushalani NI. Principles of Targeted Therapy for Melanoma. Surg Clin North Am. 2020;100(1):175–188.
   PubMed Web of Science ®Google Scholar
• Da R, Wang M, Jiang H, et al. BRAF (AMP) Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF (V600E). Front Oncol. 2020;10:531968.
   PubMed Web of Science ®Google Scholar
• Dulgar O, Kutuk T, Eroglu Z. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies. Am J Clin Dermatol. 2021;22(1):1–10.
   PubMed Web of Science ®Google Scholar
• Flaherty KT. BRAF inhibitors and melanoma. Cancer J. 2011;17(6):505–511.
   PubMed Web of Science ®Google Scholar
• Patel H, Yacoub N, Mishra R, et al. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers (Basel). 2020;12(2):2.
   Web of Science ®Google Scholar
• Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;395(10240):1835–1844.
   PubMed Web of Science ®Google Scholar
• Khaddour K, Kurn H, Zito PM. Vemurafenib. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021. StatPearls Publishing LLC; 2021.
   Google Scholar
• Cragg GM. Natural product drug discovery and development: the United States National Cancer Institute role. P R Health Sci J. 2002;21(2):97–111.
   PubMedGoogle Scholar
• Cragg GM, Newman DJ. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta. 2013;1830(6):3670–3695.
   PubMed Web of Science ®Google Scholar
• How CW, Ong YS, Low SS, et al. How far have we explored fungi to fight cancer? Semin Cancer Biol. 2021. DOI:10.1016/j.semcancer.2021.03.009
   PubMed Web of Science ®Google Scholar
• Zhong S, Li W, Bai Y, et al. Computational study on new natural compound agonists of stimulator of interferon genes (STING). PLoS One. 2019;14(5):e0216678.
   PubMed Web of Science ®Google Scholar
• Shin Low S, Pan Y, Ji D, et al. Smartphone-based portable electrochemical biosensing system for detection of circulating microRNA-21 in saliva as a proof-of-concept. Sens Actuators B Chem. 2020;308:127718.
   Web of Science ®Google Scholar
• Sterling T, Irwin JJ. ZINC 15--Ligand Discovery for Everyone. J Chem Inf Model. 2015;55(11):2324–2337.
   PubMed Web of Science ®Google Scholar
• Rao SN, Head MS, Kulkarni A, et al. Validation studies of the site-directed docking program LibDock. J Chem Inf Model. 2007;47(6):2159–2171.
   PubMed Web of Science ®Google Scholar
• Brooks BR, Brooks CL 3rd, Mackerell AD Jr., et al. CHARMM: the biomolecular simulation program. J Comput Chem. 2009;30(10):1545–1614.
   PubMed Web of Science ®Google Scholar
• Han Y, Zhang J, Hu CQ, et al. In silico ADME and Toxicity Prediction of Ceftazidime and Its Impurities. Front Pharmacol. 2019;10:434.
   PubMed Web of Science ®Google Scholar
• Gagnon JK, Law SM, Brooks CL 3rd. Flexible CDOCKER: development and application of a pseudo-explicit structure-based docking method within CHARMM. J Comput Chem. 2016;37(8):753–762.
   PubMed Web of Science ®Google Scholar
• Tabassum H, IZ A. Molecular Docking and Dynamics Simulation Analysis of Thymoquinone and Thymol Compounds from Nigella sativa L. that Inhibits P38 Protein: probable Remedies for Hepatocellular Carcinoma. Med Chem. 2020;16(3):350–357.
   PubMed Web of Science ®Google Scholar
• Fiskus W, Mitsiades N. B-Raf Inhibition in the Clinic: present and Future. Annu Rev Med. 2016;67(1):29–43.
   PubMedGoogle Scholar
• Broman KK, Dossett LA, Sun J, et al. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opin Drug Saf. 2019;18(5):381–392.
   PubMed Web of Science ®Google Scholar